Shaw I N, Natrajan M M, Rao G S, Jesudasan K, Christian M, Kavitha M
Department of Community Health, Schieffelin Leprosy Research and Training Center, Karigiri, Vellore District, Tamil Nadu 632 106, India.
Int J Lepr Other Mycobact Dis. 2000 Dec;68(4):405-9.
Forty-six, newly detected, previously untreated multibacillary (MB) patients with a bacterial index (BI) of > or = 3+ who had received WHO/MDT for 2 years were followed up for a total duration of 424 person-years and a mean duration of 9.26 +/- 2.98 years per patient. The BIs of the patients continued to fall, and all of the patients, except one, reached skin-smear negativity. WHO/MDT was well accepted and well tolerated. Relapse, which was defined as an increase in the BI of 1+ or more with or without clinical evidence of activity, was observed in only one patient, giving a relapse rate of 2.2% or 0.23 per 100 person-years in patients with a BI of > or = 3+ after long-term follow up. This patient was started on a second course of WHO/MDT to which he responded favorably. WHO/MDT for a fixed duration of 2 years for MB patients as recommended by the WHO is vindicated.
46例新诊断的、既往未治疗的细菌指数（BI）≥3+的多菌型（MB）患者接受了2年的世界卫生组织/联合化疗（WHO/MDT），随访总时长为424人年，平均每位患者随访时长为9.26±2.98年。患者的细菌指数持续下降，除1例患者外，所有患者皮肤涂片均转为阴性。WHO/MDT的接受度和耐受性良好。复发定义为细菌指数升高1+或更高，无论有无临床活动证据，仅1例患者出现复发，在BI≥3+的患者中，经过长期随访，复发率为2.2%或每100人年0.23例。该患者开始接受第二个疗程的WHO/MDT，治疗反应良好。世界卫生组织推荐的针对MB患者固定疗程为2年的WHO/MDT方案得到了验证。
